| Celsion is a development stage oncology drug company focused on developing a portfolio of cancer treatments, including directed chemotherapies, deoxyribonucleic acid (DNA)-mediated immunotherapy and ribonucleic acid based therapies. Co.'s main product candidate is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, in a Phase III clinical trial for the treatment of primary liver cancer. Second in Co.'s pipeline is GEN-1, a DNA-mediated immunotherapy for the localized treatment of ovarian and brain cancers. Co. has two platform technologies of therapeutics for difficult-to-treat forms of cancer including: Lysolipid Thermally Sensitive Liposomes and TheraPlas. The CLSN YTD return is shown above.
The YTD Return on the CLSN YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether CLSN YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CLSN YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.